comparemela.com

Latest Breaking News On - European commission grants marketing authorisation - Page 1 : comparemela.com

DARZALEX® (daratumumab) Subcutaneous Formulation-Based

DARZALEX® (daratumumab) Subcutaneous Formulation-Based
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesRegion flamandeCraig tendlerEuropean myeloma networkJanssen pharmaceutical companies of johnsonJanssen researchGlobal medical affairsExchange commissionJanssen biotech incAmerican society of hematologyEuropean medicines agencyEuropean unionJanssen research developmentCompanies of johnsonSlate development

Janssen Presents Longer-Term Talquetamab Follow-Up Data

Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination.

United statesCastillay leópRegion flamandeTalquetamab monotherapyMaria victoria mateosEdmond chanChris heuckJanssen pharmaceutical companies of johnsonNone of the janssen pharmaceutical companiesAmerican society of clinical oncologyEuropean commission grants marketing authorisationCompanies of johnsonAmerican cancer societyEuropean medicines agencyExchange commissionUniversity hospital of salamanca

Janssen Presents First Data from MajesTEC-2 Trial of

Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium, Dec. 10, 2022 (GLOBE NEWSWIRE) The.

United statesRegion flamandeEmma searleSen zhuangEdmond chanAmerican society of clinical oncologyInternational myeloma working groupJanssen biotech incJanssen research developmentJanssen pharmaceutical companiesAmerican society for transplantationJanssen pharmaceutical companies of johnsonAmerican society of hematologyClinical researchCommittee for medicinal products human useAmerican cancer society

Janssen: New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pre-treated Patients with Multiple Myeloma

Phase 1b results of teclistamab in combination with DARZALEX? (daratumumab) subcutaneous (SC) also presented at ASH 2021 Annual Meeting1,2 The Janssen Pharmaceutical Companies of Johnson Johnson

United statesNoah reymondYusri elsayedEdmond chan mbchPhilippe moreauJessica mooreJanssen biotech incAmerican society of hematology annual meetingAmerican society of clinical oncologyCancer research instituteDrugs take center stage in myelomaJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyUniversity hospital

New Clinical and Real-World Data Support Use of DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma

Investigational daratumumab quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients with multiple myeloma in randomised Phase 2 GRIFFIN study1 Real-world.

United statesEdmond chan mbchJacob laubachImran khanAmerican society of clinical oncologyJanssen biotech incAmerican society of hematology annual meetingJerome lipper multiple myeloma centerJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyJanssen scientific affairsDana farber cancer instituteAmerican cancer societyNone of the janssen pharmaceutical companiesEuropean commission

vimarsana © 2020. All Rights Reserved.